$5.81
11.97% day before yesterday
NYSE, Oct 24, 10:19 pm CET
ISIN
US92332V1070
Symbol
VTYX

Ventyx Biosciences Stock price

$5.81
+3.06 111.27% 1M
+4.55 361.11% 6M
+3.62 165.30% YTD
+3.62 165.30% 1Y
-22.15 79.22% 3Y
-15.21 72.36% 5Y
-15.21 72.36% 10Y
-15.21 72.36% 20Y
NYSE, Closing price Fri, Oct 24 2025
-0.79 11.97%
ISIN
US92332V1070
Symbol
VTYX
Industry

Key metrics

Basic
Market capitalization
$414.3m
Enterprise Value
$205.3m
Net debt
positive
Cash
$209.0m
Shares outstanding
71.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
2.0
Financial Health
Equity Ratio
91.9%
Return on Equity
-53.2%
ROCE
-59.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-129.1m | $-116.0m
EBIT
$-130.4m | $-130.0m
Net Income
$-119.0m | $-121.8m
Free Cash Flow
$-105.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
30.2% | 21.2%
EBIT
29.8% | 12.4%
Net Income
30.5% | 9.9%
Free Cash Flow
33.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.7
FCF per Share
$-1.5
Short interest
2.1%
Employees
81
Rev per Employee
$0.0
Show more

Is Ventyx Biosciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,040 stocks worldwide.

Ventyx Biosciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Ventyx Biosciences forecast:

11x Buy
79%
3x Hold
21%

Analyst Opinions

14 Analysts have issued a Ventyx Biosciences forecast:

Buy
79%
Hold
21%

Financial data from Ventyx Biosciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 30 30
8% 8%
-
- Research and Development Expense 101 101
34% 34%
-
-129 -129
30% 30%
-
- Depreciation and Amortization 1.30 1.30
60% 60%
-
EBIT (Operating Income) EBIT -130 -130
30% 30%
-
Net Profit -119 -119
31% 31%
-

In millions USD.

Don't miss a Thing! We will send you all news about Ventyx Biosciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ventyx Biosciences Stock News

Neutral
Seeking Alpha
3 days ago
Ventyx Biosciences, Inc. (NASDAQ:VTYX ) Discusses Positive Phase II Results of VTX3232 in Obesity and Cardiovascular Risk Factors October 22, 2025 4:30 PM EDT Company Participants Alex Schwartz Raju Mohan - Founder, CEO, President & Director Mark Forman Roy Gonzales - Senior VP of Finance and Principal Financial & Accounting Officer Conference Call Participants Antonio Abbate Peter Libby Lin Ts...
Neutral
GlobeNewsWire
4 days ago
VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide VTX3232 monotherapy achieved ~80% reduction in hsCRP within the first week VTX3232 monotherapy reduced IL-6 levels at Week 12 below the threshold for cardiovascular risk of ≤1.65ng/L 1 Statistically significant reductions in Lp(a) and liver inflammation No effect o...
Neutral
GlobeNewsWire
2 months ago
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the following upcoming investor conferences: 2025 Wells Fargo ...
More Ventyx Biosciences News

Company Profile

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.

Head office United States
CEO Raju Mohan
Employees 81
Founded 2018
Website ventyxbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today